TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

This article has no abstract
Epistemonikos ID: d67decc088fa72c8b0198b155e3e492fa99b7e80
First added on: Feb 11, 2025